Fig. 4From: The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the Prostaglandin E2 human model of headacheIndividual (open geometric shapes) and mean (filled geometric shapes) plasma concentration of BGC20-1531on placebo and either active day. Significant difference between AUCPC on BGC20-1531 400 mg pretreatment and BGC20-1531 200 mg pretreatment (P = 0.036) (paired t test)Back to article page